Related Experiment Video
Updated: Jan 29, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
14.5K
Microglia-Targeted Nanotherapeutics in Major Depressive Disorder: An Integrative Perspective on Neuroinflammation and
Pablo R da Silva1,2,3, Nayana M M V Barbosa2,3, Joandra M da Silva Leite4
1Postgraduate Program of Dentistry (PPGO), Health Sciences Center, Federal University of Paraíba, João Pessoa 58051-900, PB, Brazil.
Pharmaceutics
|January 28, 2026
Summary
Nanotechnology offers a novel approach for major depressive disorder (MDD) by targeting neuroinflammation. Nanocarriers modulate microglial activation, enhancing antidepressant efficacy and offering new therapeutic strategies for MDD.
Area of Science:
- Neuroscience
- Pharmacology
- Biotechnology
Background:
- Major depressive disorder (MDD) involves complex neurobiology, including neuroinflammation and microglial activation.
- Current antidepressants have limitations in efficacy, side effects, and patient adherence.
Purpose of the Study:
- To explore microglia as therapeutic targets in MDD.
- To review nanotechnology-based drug delivery systems for targeting neuroinflammation in MDD.
- To examine nanocarriers' potential to modulate microglial activation and enhance antidepressant therapy.
Main Methods:
- Narrative review of preclinical studies on nanotechnology and MDD.
- Analysis of nanocarrier strategies for modulating microglial phenotypes (M1/M2).
- Evaluation of nanocarrier impact on blood-brain barrier penetration and neuroprotection.
Main Results:
- Nanoparticle systems show promise in improving drug bioavailability and brain targeting for MDD treatment.
- Nanocarriers can modulate microglial activation, shifting towards an anti-inflammatory M2 phenotype.
- Preclinical data indicate nanocarriers reduce oxidative stress, promote neurogenesis, and restore synaptic plasticity.
Conclusions:
- Nanotechnology presents a promising avenue for precision neuropsychopharmacology in MDD.
- Targeting microglia with nanocarrier-based strategies could revolutionize MDD treatment paradigms.
- Nanotechnology offers enhanced efficacy and targeted delivery for managing MDD-associated neuroinflammation.
Related Concept Videos
01:27Depressive Disorders: Etiology
477
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
477
01:27Depressive Disorders: MDD and Dysthymia
765
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
765
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.1K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.1K
01:16Drug Delivery: Overview
827
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
827
01:05Long-term Depression
33.2K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.2K
01:18Drug Delivery: Enteral Route
1.7K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
1.7K